Esperion Therapeutics, Inc. ESPR
At closeJul 13, 2026, 4:00 PM EDT
After hours · Jul 13, 4:00 PM ET
52-week range unavailable
- YTD
- -14.05%
- 1 year
- +211.76%
- Market cap
- 441.36M
- Revenue (ttm)
- 295.45M
- Profit margin
- -29.37%
- Shares out
- 197.04M
- Forward P/E
- 11.20
- YTD return
- -14.05%
- 1-year return
- +211.76%
- Open
- 3.18
- Previous close
- 3.18
- Day's range
- 3.18 – 3.18
- Beta
- 0.95
- Analysts
- Buy
- Price target
- 7.51 (+136.1%)
2Y +1.06 (+50.00%)
Key statistics
- Enterprise value
- 555.75M
- PEG ratio
- 0.00
- Price / sales
- 1.49
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 52.00%
- Free cash flow
- -8.95M
- Total cash
- 144.72M
- Total debt
- 268.96M
- Return on equity
- 0.00%
- Short % of float
- 15.52%
- 50-day average
- 2.41
- 200-day average
- 2.24
Analyst view
Consensus: buy
- Target (low)
- 2.05
- Target (mean)
- 7.51
- Target (high)
- 16.00
- Strong buy3
- Buy2
- Hold1
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.12529.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.14 | -0.15 | -0.01 | -7.14% |
| Aug 12, 2024 | Jun 1, 2024 | -0.15 | -0.05 | +0.10 | +66.67% |
| May 7, 2024 | Mar 1, 2024 | -0.08 | 0.34 | +0.42 | +525.00% |
| Feb 27, 2024 | Dec 1, 2023 | -0.53 | -0.50 | +0.03 | +5.66% |
| Nov 7, 2023 | Sep 1, 2023 | -0.42 | -0.37 | +0.05 | +11.90% |
| Aug 1, 2023 | Jun 1, 2023 | -0.63 | -0.46 | +0.17 | +26.98% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | Cantor Fitzgerald | init | — | Overweight |
| Dec 13, 2024 | Needham | reit | Buy | Buy |
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 3, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- esperion.com
News
Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 
Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio 
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger 
10 Health Care Stocks With Whale Alerts In Today’s Session 
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR 
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 
ESPR Stock Surges 44% in a Month: Here's What You Need to Know 
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKC
Your note
Sign in to keep a note on ESPR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARROLL J MARTIN | Director | Stock Award(Grant) | May 22, 2024 | 64,650 |
| FISCHER SETH H Z | Director | Stock Award(Grant) | May 22, 2024 | 28,150 |
| FOODY JOANNE MICALE | Officer | Sale | Jul 16, 2024 | 272,862 |
| FUHRMAN ALAN CPA | Director | Stock Award(Grant) | May 22, 2024 | 53,404 |
| GOTTO ANTONIO M JR | Director | Stock Award(Grant) | May 22, 2024 | 51,599 |
| HALLADAY BENJAMIN | Chief Financial Officer | Sale | Dec 16, 2024 | 240,691 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Advisors LP | 11.85% | 23,346,013 | 52.30M | Sep 29, 2024 |
| Blackrock Inc. | 7.24% | 14,264,975 | 31.95M | Sep 29, 2024 |
| Vanguard Group Inc | 6.62% | 13,043,077 | 29.22M | Sep 29, 2024 |
| Bellevue Group AG | 5.05% | 9,944,064 | 22.27M | Sep 29, 2024 |
| Two Seas Capital Lp | 3.34% | 6,584,278 | 14.75M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.20% | 4,331,314 | 9.70M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Ultra Growth Fund | 3.39% | 6,675,165 | 14.95M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.14% | 6,179,587 | 13.84M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.47% | 4,866,712 | 10.90M | Oct 30, 2024 |
| Wasatch Small Cap Growth Fund | 2.23% | 4,397,143 | 9.85M | Sep 29, 2024 |
| Wasatch Microcap Fund | 2.14% | 4,211,030 | 9.43M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.31% | 2,575,610 | 5.77M | Sep 29, 2024 |